Quibim's Leap into the U.S. Market: A $50M Investment in Precision Medicine
January 29, 2025, 3:38 pm
Location: Spain, Valencian Community, Valencia
Employees: 51-200
Founded date: 2012
Total raised: $59.28M
In the world of health technology, precision is paramount. Quibim, a Valencia-based healthtech company, has just secured a significant $50 million in Series A financing. This funding is not just a number; it’s a lifeline aimed at transforming the landscape of medical imaging and diagnostics.
Led by Asabys and Buenavista Equity Partners, this funding round attracted a constellation of investors, including GoHub Ventures and UI Investissements. Existing backers like Amadeus Capital Partners and APEX Ventures also joined the fray, underscoring the confidence in Quibim’s vision.
Quibim’s mission is clear: to harness the power of imaging data to enhance patient outcomes. The company is not merely another player in the healthtech arena; it’s a pioneer. With tools that unlock the secrets hidden within MRI, CT, and PET scans, Quibim is setting the stage for a new era in precision medicine.
Founded in 2012 by Dr. Ángel Alberich-Bayarri and Luis Martí Bonmatí, Quibim is driven by a singular goal: to create a comprehensive, non-invasive understanding of human health. Imagine a digital twin of the human body, a dynamic model that reflects real-time health status. This is not science fiction; it’s Quibim’s ambition.
The company’s product lineup is impressive. The flagship QP-Prostate® enhances prostate cancer detection through AI-powered lesion identification. QP-Brain® quantifies early-stage neurological diseases, while QP-Liver® diagnoses diffuse liver diseases with precision. These tools are not just innovative; they are regulatory-cleared and integrated into the workflows of over 170 healthcare institutions worldwide.
Quibim’s partnerships amplify its reach. Collaborations with pharmaceutical giants like Merck KGaA and Philips are paving the way for groundbreaking advancements. For instance, the partnership with Merck focuses on developing imaging biomarker models that predict cancer patients' responses to immunotherapy. This is a game-changer in drug development, allowing for more informed decisions and better patient outcomes.
The company’s ambition doesn’t stop at organ-level digital twins. As the volume of imaging data surges, Quibim aims to analyze the entire body. This vision is not just about technology; it’s about revolutionizing healthcare. By bridging the gap between research, clinical practice, and drug development, Quibim is poised to redefine how we approach diagnostics.
The recent funding will bolster Quibim’s efforts to establish a robust presence in the U.S. market. This is a critical move. The U.S. healthcare landscape is vast and complex, but it also offers immense opportunities. Strategic collaborations with hospitals and pharmaceutical companies will be essential. Quibim is not just entering a market; it’s making a statement.
Investors are excited. The backing from Asabys and Buenavista reflects a belief in Quibim’s potential to transform imaging diagnostics. Their innovative approach addresses critical needs in oncology, neurology, and beyond. This funding is not just an investment; it’s a vote of confidence in a future where imaging data drives clinical decisions.
Quibim’s technology exemplifies the next wave of precision medicine. It’s about more than just data; it’s about actionable insights. The company’s ability to combine AI with imaging biomarker discovery is setting new standards. This is not just a trend; it’s a paradigm shift.
As Quibim continues to grow, its impact on global healthcare will be profound. The company is not just developing products; it’s shaping the future of medicine. With a strong foundation in Europe, the leap into the U.S. market is a natural progression.
The healthcare industry is evolving. Patients demand more personalized care, and Quibim is answering that call. By unlocking the potential of imaging, the company is paving the way for better diagnostics and treatment plans.
In conclusion, Quibim’s $50 million funding is more than a financial boost; it’s a catalyst for change. The company is on a mission to revolutionize healthcare through precision medicine. With a strong product portfolio, strategic partnerships, and a clear vision, Quibim is poised to make waves in the U.S. market. The future of health technology is bright, and Quibim is leading the charge.
Led by Asabys and Buenavista Equity Partners, this funding round attracted a constellation of investors, including GoHub Ventures and UI Investissements. Existing backers like Amadeus Capital Partners and APEX Ventures also joined the fray, underscoring the confidence in Quibim’s vision.
Quibim’s mission is clear: to harness the power of imaging data to enhance patient outcomes. The company is not merely another player in the healthtech arena; it’s a pioneer. With tools that unlock the secrets hidden within MRI, CT, and PET scans, Quibim is setting the stage for a new era in precision medicine.
Founded in 2012 by Dr. Ángel Alberich-Bayarri and Luis Martí Bonmatí, Quibim is driven by a singular goal: to create a comprehensive, non-invasive understanding of human health. Imagine a digital twin of the human body, a dynamic model that reflects real-time health status. This is not science fiction; it’s Quibim’s ambition.
The company’s product lineup is impressive. The flagship QP-Prostate® enhances prostate cancer detection through AI-powered lesion identification. QP-Brain® quantifies early-stage neurological diseases, while QP-Liver® diagnoses diffuse liver diseases with precision. These tools are not just innovative; they are regulatory-cleared and integrated into the workflows of over 170 healthcare institutions worldwide.
Quibim’s partnerships amplify its reach. Collaborations with pharmaceutical giants like Merck KGaA and Philips are paving the way for groundbreaking advancements. For instance, the partnership with Merck focuses on developing imaging biomarker models that predict cancer patients' responses to immunotherapy. This is a game-changer in drug development, allowing for more informed decisions and better patient outcomes.
The company’s ambition doesn’t stop at organ-level digital twins. As the volume of imaging data surges, Quibim aims to analyze the entire body. This vision is not just about technology; it’s about revolutionizing healthcare. By bridging the gap between research, clinical practice, and drug development, Quibim is poised to redefine how we approach diagnostics.
The recent funding will bolster Quibim’s efforts to establish a robust presence in the U.S. market. This is a critical move. The U.S. healthcare landscape is vast and complex, but it also offers immense opportunities. Strategic collaborations with hospitals and pharmaceutical companies will be essential. Quibim is not just entering a market; it’s making a statement.
Investors are excited. The backing from Asabys and Buenavista reflects a belief in Quibim’s potential to transform imaging diagnostics. Their innovative approach addresses critical needs in oncology, neurology, and beyond. This funding is not just an investment; it’s a vote of confidence in a future where imaging data drives clinical decisions.
Quibim’s technology exemplifies the next wave of precision medicine. It’s about more than just data; it’s about actionable insights. The company’s ability to combine AI with imaging biomarker discovery is setting new standards. This is not just a trend; it’s a paradigm shift.
As Quibim continues to grow, its impact on global healthcare will be profound. The company is not just developing products; it’s shaping the future of medicine. With a strong foundation in Europe, the leap into the U.S. market is a natural progression.
The healthcare industry is evolving. Patients demand more personalized care, and Quibim is answering that call. By unlocking the potential of imaging, the company is paving the way for better diagnostics and treatment plans.
In conclusion, Quibim’s $50 million funding is more than a financial boost; it’s a catalyst for change. The company is on a mission to revolutionize healthcare through precision medicine. With a strong product portfolio, strategic partnerships, and a clear vision, Quibim is poised to make waves in the U.S. market. The future of health technology is bright, and Quibim is leading the charge.